# 研究

## 我们的研究重点

Joe Yeong 实验室致力于通过创新研究和计算方法推进空间组学领域。

### 当前研究领域

#### 空间转录组学

我们开发和应用尖端的空间转录组学技术，以了解天然组织环境中的基因表达模式。

#### 多组学整合

我们实验室专门整合多个组学数据集，为生物系统提供全面的见解。

#### 计算生物学

我们开发新的计算方法和算法来分析复杂的空间组学数据。

#### 生物标志物发现

通过我们的研究，我们识别和验证各种疾病和生物过程的生物标志物。

### 研究项目

*[具体研究项目待详细说明]*

### 研究方法

- 单细胞和空间转录组学
- 计算数据分析
- 机器学习应用
- 统计建模
- 生物信息学流程开发

### 合作

我们积极与全球研究人员和机构合作，推进对空间生物学的理解。

### 资助

我们的研究得到各种资助机构和机构的支持（自 2017 年以来获得超过 2000 万美元）。

获得的项目资助包括：
- NMRC LCG - CLARION：通过研究和创新攻克各期肺癌（角色：主题 PI）
- NMRC LCG - SYMPHONY 2.0：新加坡淋巴瘤转化研究（角色：主题 PI）
- NMRC CIA - DATANG：开发基于 AI 深度学习的病理解决方案，用于肿瘤学临床试验分配的预测性生物标志物预测（角色：首席 PI）
- NRF CRP - NICHES：高风险癌症亚型中利基驱动的免疫逃逸和转移的有效分层（角色：团队 PI）
- NIH R01 - EBV 特异性 T 细胞在 EBV 驱动的鼻咽癌检查点阻断免疫治疗反应中的作用（角色：联合 PI）
- MOH CSA - ENIGMA：阐明鼻咽癌中的免疫重编程（角色：联合 PI）
- A*STAR IAF-ICP - 癌症患者循环细胞环境的系统单细胞分辨率分析（角色：首席 PI）
- A*STAR IAF-ICP - 开发 AI 驱动的可扩展高通量成像检测，用于识别癌症疫苗的免疫性肿瘤相关抗原（角色：首席 PI）

---

## 发表论文

### 近期发表论文

1. Spatial immune scoring system predicts hepatocellular carcinoma recurrence. Nature
2. Mixture of experts in large language models. arXiv preprint
3. A Foundation Model for Spatial Proteomics. arXiv preprint
4. The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then? Cancer Personalized Treatment
5. An integrated approach for analyzing spatially resolved multi-omics datasets from the same tissue section. Frontiers in Molecular Biosciences
6. Asia's emergence in cancer immunotherapy: challenges and opportunities. Journal for ImmunoTherapy of Cancer
7. Training immunophenotyping deep learning models with the same-section ground truth cell label derivation method improves virtual staining accuracy. Response/Resistance to PD-1 Axis Inhibitors
8. Advancing Tissue Biology Research With Weave Software For Spatial Multi-Omics. MDPI
9. H&E 2.0: deep learning prediction of lung cancer biomarkers pan-cytokeratin and PD-L1 using a dual model framework. Journal for ImmunoTherapy of Cancer
10. A Novel Manual "Centrifuged-Enhanced" Cytosmear Technique for Improving Hypocellular Cytology in the Diagnosis of Vitreoretinal Lymphoma. Translational Vision Science & Technology
11. Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024. Cancer Research
12. Achieving Trustworthy Real-Time Decision Support Systems with Low-Latency Interpretable AI Models. arXiv preprint
13. Developing cell-based therapies for pancreatic ductal adenocarcinoma. The Journal of Clinical Investigation
14. Single‐Cell Profiling: Any Scale, Any Size, All at Once. Advanced Science

### 所有发表论文

#### 2025

1. Spatial immune scoring system predicts hepatocellular carcinoma recurrence
2. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
3. Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution
4. Nonuniversality of inflammaging across human populations
5. A Foundation Model for Spatial Proteomics
6. Mixture of experts in large language models
7. Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes
8. Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment
9. The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?
10. An integrated approach for analyzing spatially resolved multi-omics datasets from the same tissue section
11. Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis
12. Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
13. Asia's emergence in cancer immunotherapy: challenges and opportunities
14. Single cell AI-prediction of protein biomarker on novel whole slide unstained blood smear images
15. EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer
16. Manufacturing characteristics and early outcomes of a tandem aCD22-aCD19 CAR-T therapy for childhood and adult relapsed/refractory acute precursor B lymphoblastic leukemia
17. Training immunophenotyping deep learning models with the same-section ground
18. Advancing Tissue Biology Research With Weave Software For Spatial Multi-Omics
19. 1089 H&E 2.0: deep learning prediction of lung cancer biomarkers pan-cytokeratin and PD-L1 using a dual model framework
20. 1106 H&E 3.0: Pix2Pix-based virtual haematoxylin and eosin staining from greyscale images with feature comparison
21. Multiomic signatures of durable response in a Phase I/II trial of tandem aCD22-aCD19 CAR-T therapy for relapsed B-lineage acute lymphoblastic leukaemia
22. A Novel Manual "Centrifuged-Enhanced" Cytosmear Technique for Improving Hypocellular Cytology in the Diagnosis of Vitreoretinal Lymphoma
23. Author Correction: Spatial immune scoring system predicts hepatocellular carcinoma recurrence
24. Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024
25. Achieving Trustworthy Real-Time Decision Support Systems with Low-Latency Interpretable AI Models
26. Using longitudinal spatial-omics to demonstrate in-situ Epstein-Barr virus reduction in responders to immunotherapy treated nasopharyngeal cancer.
27. Lung cancer risk prediction in Asian populations: A study of immune signatures from the Singapore Longitudinal Ageing Studies
28. Longitudinal blood-based immuno-monitoring reveals distinct immune profiles in colorectal cancer patients with divergent responses to first-line systemic therapy
29. The aged tumor microenvironment limits T cell control of breast cancer
30. Decoding cancer prevention: Exercise, dark proteome signatures, and spatial proteomics
31. Developing cell-based therapies for pancreatic ductal adenocarcinoma
32. Single‐Cell Profiling: Any Scale, Any Size, All at Once
33. Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment

#### 2024

1. Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer
2. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
3. Bioengineered hydrogels enhance ex vivo preservation of patient-derived tumor explants for drug evaluation
4. Spatial omics techniques and data analysis for cancer immunotherapy applications
5. Platelet TLR7 is essential for the formation of platelet–neutrophil complexes and low-density neutrophils in lupus nephritis
6. The prognostic value of CD39 as a marker of tumor-specific T cells in triple-negative breast cancer in Asian women
7. Advancements and applications of AI technologies in pathology: a scoping review
8. Training immunophenotyping deep learning models with the same-section ground truth cell label derivation method improves virtual staining accuracy
9. Regulation of non‐canonical proteins from diverse origins through the nonsense‐mediated mRNA decay pathway
10. Bioactive polyethylene-coated nonwovens for wound healing application
11. The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma
12. Inflammasome-Driven Fatal Acute-on-Chronic Liver Failure Triggered by Mild COVID-19
13. Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability
14. Deciphering MARCH5's impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling
15. 831 Introducing a software package for integrated visualization and data analysis of spatial omics datasets
16. 1250 H&E-based cell prediction multi-classification models to capture morphologically distinct subpopulations of CD8+ T cells
17. A PHASE 1 DOSE ESCALATION STUDY OF EBC-129, A FIRST-IN CLASS, ANTI N-GLYCOSYLATED CEACAM5 & CEACAM6 ANTIBODY-DRUG CONJUGATE (ADC) IN PATIENTS WITH SOLID TUMORS
18. A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA).
19. Association between CH mutation in TET2and solid cancer in elderly Asian women.
20. A universal pipeline to combine spatial transcriptomics, proteomics, and diagnostic H&E assays on a single tissue section to study tissue microenvironment.
21. Advances in AI-Enhanced Biomedical Imaging for Cancer Immunology
22. Automated Hyperplex Protein Staining and Imaging System on Lung Adenocarcinoma Tissue using off-the-shelf Primary Antibodies
23. INFLAMM-AGING IS NOT A UNIVERSAL AGING MECHANISM ACROSS DIVERSE HUMAN POPULATIONS
24. Aristolochic acid‐related renal cell carcinoma exhibits a distinct tumor‐immune microenvironment favoring response to immune checkpoint blockade
25. Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4; 14)
26. 1249 Improving CD8+ cell detection in spatial immunology with generalizable H&E deep learning models trained on diverse clinical scanners
27. 119 Auto-imaging cytometry on the slide (ICOS) for quality control of CAR-T products
28. 1348 Evaluation of a cancer vaccine targeting MAGED4B in preventing oral cancer development from oral epithelial dysplasia
29. 1213 Development and multiplexing of virtual immuno-oncology biomarkers for enhanced research and discovery
30. 1221 Deciphering cellular features: StyleGAN for enhancing H&E cell classification
31. P3. 03I. 06 Neoadjuvant Gefitinib in EGFR Mutated NSCLC (a Phase 2 Window-Of-Opportunity Study): Deep Genomic and Transcriptomic Analysis
32. Effect of tumor-immune microenvironment (TIME) on disparate ascending (A) and descending (D) subtypes of nasopharyngeal carcinoma (NPC).
33. Abstract P69: Immune Landscape of BRCA1/2 -mutated Breast and Ovarian Cancers in an Asian Cohort
34. Abstract LT09: Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies
35. Abstract LB252: iCellSight: An interactive tool for analyzing and visualizing in-situ high-plex cellular protein data
36. Prognostic Impact of Tertiary Lymphoid Structures in Triple-Negative Breast Cancer
37. Spatial Analysis of the Tumor Microenvironment and Gene Expression in LSD1-expressing Triple-negative Breast Cancer (TNBC)
38. H&E2. 0—Harnessing Artificial Intelligence to Enhance Biomarker Prediction Using Hematoxylin and Eosin-Stained Image
39. A case of metastatic lymphoepithelial carcinoma of parotid gland identified on 68gallium DOTA-[Tyr3] octreotate PET CT

*(Due to the extensive publication list, only recent years are shown. For complete list, please refer to the English version.)*
